TNG Stock Overview
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Transgene SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.33 |
| 52 Week High | €2.55 |
| 52 Week Low | €1.03 |
| Beta | 0.72 |
| 1 Month Change | 17.49% |
| 3 Month Change | -0.60% |
| 1 Year Change | -29.41% |
| 3 Year Change | -48.65% |
| 5 Year Change | -55.67% |
| Change since IPO | -97.05% |
Recent News & Updates
Recent updates
Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near Term
Mar 21
Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 19Does Transgene (EPA:TNG) Have A Healthy Balance Sheet?
Mar 18Transgene (EPA:TNG) Has Debt But No Earnings; Should You Worry?
Nov 24Health Check: How Prudently Does Transgene (EPA:TNG) Use Debt?
Apr 16What Type Of Shareholders Own The Most Number of Transgene SA (EPA:TNG) Shares?
Mar 12Does Transgene's (EPA:TNG) Share Price Gain of 62% Match Its Business Performance?
Jan 23
Shareholder Returns
| TNG | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -8.1% | -1.4% | -0.1% |
| 1Y | -29.4% | -13.0% | 1.3% |
Return vs Industry: TNG underperformed the French Biotechs industry which returned -13% over the past year.
Return vs Market: TNG underperformed the French Market which returned 1.3% over the past year.
Price Volatility
| TNG volatility | |
|---|---|
| TNG Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.5% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: TNG has not had significant price volatility in the past 3 months.
Volatility Over Time: TNG's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 143 | Alessandro Riva | www.transgene.fr |
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors.
Transgene SA Fundamentals Summary
| TNG fundamental statistics | |
|---|---|
| Market cap | €133.75m |
| Earnings (TTM) | -€22.33m |
| Revenue (TTM) | €7.90m |
16.9x
P/S Ratio-6.0x
P/E RatioIs TNG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TNG income statement (TTM) | |
|---|---|
| Revenue | €7.90m |
| Cost of Revenue | €29.59m |
| Gross Profit | -€21.69m |
| Other Expenses | €640.00k |
| Earnings | -€22.33m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -0.22 |
| Gross Margin | -274.53% |
| Net Profit Margin | -282.63% |
| Debt/Equity Ratio | 110.8% |
How did TNG perform over the long term?
See historical performance and comparison